Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) announced its financial results for the first quarter of fiscal 2026, ending June 30, 2025. The company reported a 37% year-over-year increase in global medical cannabis net revenue, reaching $64.8 million. International medical cannabis net revenue rose by 85% to $37.1 million, with significant growth observed in markets such as Germany and Poland. Aurora also delivered a growth in adjusted EBITDA of over 200%, totaling $10.8 million, and generated a positive free cash flow of $9.2 million, marking a 42% increase year-over-year. The company maintains a strong balance sheet with approximately $186 million in cash and a debt-free cannabis business. The international medical cannabis segment, which is the company's highest-margin segment, now represents 57% of its global medical cannabis net revenue. Additionally, Bevo, Aurora's plant propagation business, contributed further to revenue diversification and growth through seasonal strength and organic expansion. Aurora expects to generate positive annual free cash flow for the second consecutive year, emphasizing its operational execution and distinction from peers.